LitAlert ~~ GeneLit.com

    • Development of a novel BRCAness score that predicts response to PARP inhibitors.
    • Oshi M, Gandhi S, Wu R, Asaoka M, Yan L, Yamada A, Yamamoto S, Narui K, Chishima T, Ishikawa T, Endo I, Takabe K.
    • Biomark Res. 2022 Nov 12;10(1):80. doi: 10.1186/s40364-022-00427-8.

    • Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.
    • Smith HL, Willmore E, Mukhopadhyay A, Drew Y, Curtin NJ.
    • Cancers (Basel). 2022 Nov 12;14(22):5559. doi: 10.3390/cancers14225559.

    • Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer.
    • Hollasch M, Antonarakis ES.
    • OncLive. 2022 Nov 11.

    • Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing.
    • Rosa K, Antonarakis ES.
    • OncLive. 2022 Nov 11.

    • Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPC.
    • Antonarakis ES.
    • OncLive. OncLive TV. 2022 Nov 11.

    • Dr. Shore on the Importance of Genetic Testing in Prostate Cancer.
    • Shore N.
    • OncLive. OncLive TV. 2022 Nov 11.

    • The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
    • Uemura H, Oya M, Kamoto T, Sugimoto M, Shinozaki K, Morita K, Koto R, Takahashi M, Nii M, Shin E, Nonomura N.
    • Cancer Med. 2022 Nov 10. doi: 10.1002/cam4.5333. Epub ahead of print.

    • PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer.
    • Doherty K, Miller EM.
    • OncLive. 2022 Nov 10.

    • Molecular Management of High-Grade Serous Ovarian Carcinoma.
    • Punzón-Jiménez P, Lago V, Domingo S, Simón C, Mas A.
    • Int J Mol Sci. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777.

    • Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction.
    • De Jong D, Otify M, Chen I, Jackson D, Jayasinghe K, Nugent D, Thangavelu A, Theophilou G, Laios A.
    • Medicina (Kaunas). 2022 Nov 8;58(11):1611. doi: 10.3390/medicina58111611.

    • Partial Reduction in BRCA1 Gene Dose Modulates DNA Replication Stress Level and Thereby Contributes to Sensitivity or Resistance.
    • Classen S, Rahlf E, Jungwirth J, Albers N, Hebestreit LP, Zielinski A, Poole L, Groth M, Koch P, Liehr T, Kankel S, Cordes N, Petersen C, Rothkamm K, Pospiech H, Borgmann K.
    • Int J Mol Sci. 2022 Nov 1;23(21):13363. doi: 10.3390/ijms232113363.